The potential role of sunitinib in gastrointestinal cancers other than GIST

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 1, 2010, Pages 36-43

  Grávalos, Cristina ^a   Grande, Enrique ^b   Gasent, Joan Manel ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL MARINA ALTA   (Spain)

Author keywords

Antiangiogenic therapy; Gastrointestinal cancer; Multitargeted therapy; Sunitinib; Tyrosine kinase inhibitor; VEGF

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; AXITINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; SORAFENIB; SUNITINIB; VANDETANIB; VATALANIB;

ADENOCARCINOMA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETHARGY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALAISE; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SOFT TISSUE SARCOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; VOMITING; WEAKNESS;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PYRROLES;

EID: 77956616500     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.01.008     Document Type: Review

References (41)

1. Elkord E., Hawkins R.E., Stern P.L. Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy. Expert Opin Biol Ther 2008, 8(4):385-395.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
4. Morabito A., De Maio E., Di Maio M., et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006, 11:753-764.
5. McCarty M.F., Somcio R.J., Stoeltzing O., et al. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007, 117:2114-2122.
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124.
7. Demetri G.D., van Oosterom A.T., Garret C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
8. Chow L.Q.M., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25(7):884-896.
9. Faivre S., Delbaldo C., Vera K., et al. Safety, Pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
10. Izzedine H., Billemont B., Thibault F., Rixe O. New challenges in kidney cancer therapy: sunitinib. Ann Oncol 2007, 18(Suppl 9):ix83-ix86.
11. Bello C.L., Sherman L., Zhou J., et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multitargeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs 2006, 17:353-358.
12. Rini B.I. Sunitinib. Expert Opin Pharmacother 2007, 8:2359-2369.
13. Houk E., Bello C., Michaelson D., et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 2007, [vol. 25, No. 18S (June 20 Supplement); 2007: 5027].
14. Galizia G., Lieto E., Ferraraccio F., et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004, 10:3490-3499.
15. Takahashi Y., Kitadai Y., Bucana C.D., et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
16. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-3683.
17. Saltz L.B., Rosen L.S., Marshall J.L., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007, 25:4793-4799.
18. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
19. Marzola P., Degrassi A., Calderan L., et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005, 11(16):5827-5832.
20. Leong S., Eckhardt S.G., Chan E., et al. A phase I study of sunitinib in combination with modified FOLFOX6 chemotherapy. Gastrointestinal Cancers Symposium 2007, (abstract 285).
21. Starling N., Vazquez F., Cunningham D., et al. Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naïve metastatic colorectal cancer. J Clin Oncol 2008, 26. (abstract 3563).
22. Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer. Available at: [Accessed July 20, 2009]. http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp.
23. Aklilu M., Ilson D.H. Targeted agents and esophageal cancer-the next step. Semin Radiat Oncol 2006, 17:62-69.
24. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumor activities. Ann Oncol 2007, 18(Suppl 10):x3-x10.
25. Bang Y., Kang Y., Kang W., et al. Sunitinib as second line treatment for advanced gastric cancer: preliminary results from a phase II study. J Clin Oncol 2007, 25(18S). (abstract 4603).
26. Zhu A.X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008, 112:250-259.
27. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). N Engl J Med 2008, 359:378-390.
28. Faivre S., Raymond E., Boucher E., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10(August (8)):794-800. [Epub 2009 July 6].
29. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035.
30. De Primo S.E., Cheng A.L., Lanzalone S., et al. Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): analysis of correlations with outcome and tumor imaging parameters. J Clin Oncol 2008, 26. (abstract 4593).
31. Seo Y., Baba H., Fukuda T., et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
32. Cuneo K.C., Geng L., Fu A., et al. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiation Oncol Biol Phys 2008, 71:873-879.
33. O'Reilly E.M., Niedzwiecki D., Hollis D., et al. A phase II trial of sunitinib in previously treated pancreas adenocarcinoma, CALGB 80603. J Clin Oncol 2008, 26. (abstract 4515).
34. Strosberg J.R., Kvols L.K. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumors. Expert Opin Investig Drugs 2007, 16:219-224.
35. Hager J.H., Hanahan D. Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann N Y Acad Sci 1999, 887:150-163.
36. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005, 23:939-952.
37. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26:3403-3410.
38. Raymond E., Raoul J.L., Niccoli P., et al. Phase III, randomized, double-blind trial of Sunitinib vs placebo in patients with progressive, well-differentiated, malignant pancreatic islet cell tumors. Presented as oral communication at the World Gastrointestinal Congress 2009, (abstract O-0013).
39. Yoshikawa D., Ojima H., Iwasaki M., et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008, 29:418-425.
40. Clark J.W., Meyerhardt J.A., Sahani D.V., et al. Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic billiary tract and gallbladder cancers. J Clin Oncol 2007, 25(18S). (abstract 4625).
41. Huether A., Höpfner M., Baradari V., et al. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007, 73:1308-1317.